whatshot

CANF   $2.01  -0.99% Market Closed

Can Fite Biopharma Ltd
show_chart Advanced Chart of CANF
Last Events:

2023-08-09 Trend pattern changed from сужающийся канал to восходящий клин.

2023-08-09 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-06 Trend pattern changed from восходящий клин to сужающийся канал.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Trend pattern changed from расходящийся клин с наклоном вверх to восходящий клин.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

Current temperature: 3.17
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 13.33
Mean unverified/preliminary 13.33 / 13.33
Target Price Low / High 10.00 / 18.00
Median / STD DEV 12.00 / 4.16
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 None Buy None
ma50 ActivelyBuy None None
ma100 Buy ActivelyBuy None
Candlestick PatternNov. 19, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US13471N3008
ceo Mr. Motti Farbstein
Website https://www.canfite.com
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.